Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Why Editas Medicine's Shares Jumped This Week
12:10pm, Friday, 03'rd Feb 2023
The gene-editing biotech's shares have had a strong two-week run.
Is Editas Medicine Stock a Buy Now?
06:15am, Friday, 03'rd Feb 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
3 CRISPR Stocks to Buy Now Or You'll Be Kicking Yourself Later
12:58pm, Thursday, 02'nd Feb 2023
CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR, to try to improve human health.
Why Editas Medicine Stock Charged Higher in January
11:33am, Thursday, 02'nd Feb 2023
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.
7 CRISPR Stocks With the Best Long-Term Potential
07:10pm, Monday, 30'th Jan 2023
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease
Why Shares of Editas Medicine Jumped This Week
06:04pm, Thursday, 26'th Jan 2023
It's been a seesaw month for the clinical-stage gene-editing biotech.
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
04:03am, Thursday, 26'th Jan 2023
The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.
Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for Investors
11:19am, Wednesday, 25'th Jan 2023
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Editas (EDIT) Moves Ahead With its Portfolio Reprioritization
02:18pm, Friday, 20'th Jan 2023
Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
03:40pm, Wednesday, 18'th Jan 2023
CRISPR could revolutionize the way we treat thousands of diseases. Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material, the Cleveland
Editas Medicine, Inc. (EDIT) Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)
10:39am, Wednesday, 11'th Jan 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 7:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Baisong Mei - Chief Medica
Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs
01:32pm, Tuesday, 10'th Jan 2023
Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%.
Why Editas Medicine Stock Is Sliding Today
11:59am, Monday, 09'th Jan 2023
The gene-editing pioneer announced a big shake-up with its research and development programs.
Editas Medicine tumbles more than 7% after announcing job cuts, restructuring
11:54am, Monday, 09'th Jan 2023
Editas Medicine Inc. [s: edit] is cutting approximately 20% of its workforce. The company reported 1,800 employees as of May 31, according to its annual report.
10 Potential 10x Return Stocks For The Next 10 Years
11:04am, Wednesday, 04'th Jan 2023
While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or i
